NASPGHAN Mentor/Mentee Pilot Program 2015
Introducing a new pilot program for research and career mentorship. The target audience for this program will be pediatric gastroenterology fellows entering their 3rd year of fellowship as of July 2015.
Fellows will be paired with successful research mentors outside of their institution for a period of two years (3rd year of fellowship and first year of faculty appointment). Thus, fellows can expect guidance and unbiased feedback in their area of research from a senior mentor outside of their home institution. This will involve a monthly long-distance interaction and an annual face to face meeting at the National NASPGHAN Meeting.
The mentee’s will need formal approval from their fellowship program directors (please download and complete application form) and only a select number of mentor-mentee pairs will be inducted into the first “pilot” phase of this program.
The deadline for receipt of completed applications is June 1st 2015.
Please submit applications via email to email@example.com
- Pediatric Liver Database
- Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection
- Biliary Atresia Research Consortium (PROBE)
- A Multi-Center Group to Study Acute Liver Failure in Children
CEGIR is a NIH-funded U54 collaborative consortium of clinician-investigators, translational scientists, physicians, patients, families and patient advocacy groups, and is part of the Rare Disease Clinical Research Network (RDCRN <https://www.
CEGIR recognizes a growing need for physicians trained in eosinophilic gastrointestinal disorders (EGIDs) and the need for a greater focus in the
clinical research enterprise focused on these diseases. CEGIR grant (U54 AI117804) releases this RFA for Training Awards to physicians (fellows-in-training and junior faculty) interested in developing expertise in performing research in and providing outstanding clinical care for EGIDs.
Attached are guidelines for application and we hope to generate a robust response from our scientific community - please feel free to share with
colleagues and collaborators. Please do not hesitate to contact Jonathan Spergel (firstname.lastname@example.org) or Sandeep Gupta (email@example.com) for any questions regarding this RFA.
Hepatitis B Research Network
Hepatitis B in children can lead to social stigmatism, cirrhosis, cancer and endstage liver disease, yet our knowledge of the problem of pediatric HBV in North America is insufficient. To meet this gap, the NIDDK-funded Hepatitis B Research Network is launching both a pediatric cohort study to describe the natural history of this disease in children and a clinical trial for immunotolerant children. There are 7 pediatric sites: Johns Hopkins University School of Medicine (Kathy Schwarz, M.D., PI); St. Louis University (Jeff Teckman, M.D.); UCSF (Phil Rosenthal, M.D.); University of Minnesota (Sarah Jane Schwarzenberg, M.D.); University of Texas Southwest (Norberto Rodriguez-Baez, M.D.), University of Toronto (Simon Ling, M.D.); and the University of Washington (Karen Murray MD). We hope to enroll 500 children in the cohort study and 250 children in the immunotolerant trial. Details
Pediatric Resource Organization for Kids with Inflammatory Intestinal Diseases (PROKIIDS) and Pediatric IBD Research Network
The Pediatric IBD Research Network is now extending a request for participation to the NASPGHAN community through this communication. Our intent is to add an additional 7-10 centers to the current 13 (7 active, 6 in process of becoming active) over the next 4-6 months. The application form for centers that are interested in being considered for participation can be accessed here. Eligibility is based on qualifications as detailed on the application form and final decisions will be made by the selection committee composed of members of the Pediatric Network, the NASPGHAN IBD committee, and CCFA. Selection continues until all spots are filled and applications will be considered on a first come, first considered basis.
We appreciate your interest and look forward to your possible participation. Please contact any one of us listed here with questions.
Jeffrey Hyams, MD
Co-Chair, Selection Comm.
Robert Baldassano, MD
Co-Chair, Selection Comm.
Subra Kugathasan, MD